Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate

C. van Drunen; E. O. Meltzer; C. Bachert; J. Bousquet; W. J. Fokkens

doi:https://doi.org/10.1111/j.1398-9995.2005.00917.x

Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate

C. van Drunen, E. O. Meltzer, C. Bachert, J. Bousquet, W. J. Fokkens

Research output: Contribution to journal › Review article › Academic › peer-review

32 Citations (Scopus)

Abstract

Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis

Original language	English
Pages (from-to)	5-19
Journal	Allergy
Volume	60
Issue number	Suppl. 80
DOIs	https://doi.org/10.1111/j.1398-9995.2005.00917.x
Publication status	Published - 2005

Access to Document

https://doi.org/10.1111/j.1398-9995.2005.00917.x

Cite this

@article{c05742a7357544e8bce7bec223c6296e,

title = "Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate",

abstract = "Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis",

author = "{van Drunen}, C. and Meltzer, {E. O.} and C. Bachert and J. Bousquet and Fokkens, {W. J.}",

year = "2005",

doi = "https://doi.org/10.1111/j.1398-9995.2005.00917.x",

language = "English",

volume = "60",

pages = "5--19",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "Suppl. 80",

}

TY - JOUR

T1 - Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate

AU - van Drunen, C.

AU - Meltzer, E. O.

AU - Bachert, C.

AU - Bousquet, J.

AU - Fokkens, W. J.

PY - 2005

Y1 - 2005

N2 - Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis

AB - Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis

U2 - https://doi.org/10.1111/j.1398-9995.2005.00917.x

DO - https://doi.org/10.1111/j.1398-9995.2005.00917.x

M3 - Review article

C2 - 15948774

SN - 0105-4538

VL - 60

SP - 5

EP - 19

JO - Allergy

JF - Allergy

IS - Suppl. 80

ER -